Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TDI01 for Treatment of Moderate or Severe Chronic Graft-Versus-Host Disease After Failure of at Least 1 and Not More Than 5 Lines of Systemic Therapy: an Open Label, Multi-center, ph1/2 Study

NCT06169722 is registered in ClinicalTrials.gov with Beijing Tide Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06169722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06169722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TDI01 for Treatment of Moderate or Severe Chronic Graft-Versus-Host Disease After Failure of at Least 1 and Not More Than 5 Lines of Systemic Therapy: an Open Label, Multi-center, ph1/2 Study
Lead sponsor
Beijing Tide Pharmaceutical Co., Ltd
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 6, 2024
Completion date
August 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gvhd, chronic